| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $1.0M | +62.2% | +12.4% |
| SG&A Expense | $1.7M | +7.5% | +31.1% |
| Pre-tax Income | -$2.8M | -37.6% | -31.6% |
| Net Income | -$3.0M | -46.3% | -39.9% |
| EPS (Basic) | -$0.73 | -43.1% | +62.4% |
| EPS (Diluted) | -$0.73 | -43.1% | +62.4% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $5.2M | -25.8% | +10.2% |
| Short-term Investments | $42K | -2.5% | +2.6% |
| Current Assets | $6.9M | -21.6% | +7.5% |
| Total Assets | $9.1M | -18.4% | -1.6% |
| Current Liabilities | $2.2M | +49.4% | +20.2% |
| Total Liabilities | $2.2M |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$5.7M | — | — |
| Financing Cash Flow | $94K | — | — |
| -0.7% |
| Stockholders' Equity | $6.9M | -28.1% | -1.8% |